



A180.E1688  
JACC March 9, 2010  
Volume 55, issue 10A



## STENT FRACTURE, TASC II CD LESION AS RESTENOSIS FACTORS, AND CILOSTAZOL AS A NEGATIVE-RESTENOSIS FACTOR WITHIN A YEAR FOLLOWING NITINOL STENT IMPLANTATION IN THE SUPERFICIAL FEMORAL ARTERY

i2 Oral Contributions

Georgia World Congress Center, Room B315

Monday, March 15, 2010, 8:45 a.m.-9:00 a.m.

Session Title: Endovascular Interventions

Abstract Category: PCI - Endovascular

Presentation Number: 2905-08

Authors: *Osamu Iida, Msaaki Uematsu, Seiki Nagata, Yoshimitsu Soga, Hiroyoshi Yokoi, Masakiyo Nobuyoshi, Keisuke Hirano, Toshiya Muramatsu, Shinsuke Nanto, Kansai Rosai Hospital, Amagasaki, Japan*

**Background:** Restenosis following nitinol stent implantation in the superficial femoral artery (SFA) predominantly occurs within a year. However, factors associated with the restenosis have not been systematically studied. We sought to investigate the restenosis factors within a year following the nitinol stent implantation in the SFA.

**Methods:** This study was a multicenter, retrospective analysis for the prospective maintained database from April 2004 to December 2008. We studied 639 limbs in consecutive 510 patients with peripheral artery disease (age, 71±9 years; female, 28%; critical limb ischemia, 23%) who underwent successful endovascular therapy with nitinol stents in the SFA. Restenosis was detected by duplex ultrasound. Stent fracture was identified by X-ray. Single regression and subsequent multivariate analyses were performed to explore the independent determinants of restenosis occurred within a year.

**Results:** Average lesion length was 147±91 mm, and 45% lesions was TASC C/D. Primary patency was 80, 67, 63% at 1, 3, 5 years, respectively. Stent fracture was observed in 14% lesions. A multiple logistic analysis showed stent fracture, TASC C/D lesion and administration of cilostazol were the strong independent factors associated with the restenosis occurring within a year.

**Conclusion:** Stent fracture and TASC II CD lesion were associated with restenosis, and cilostazol was negatively associated with restenosis occurring within a year following nitinol stent implantation in the SFA.

	Hazard ratio	95% CI	P value
Female gender	1.56	0.992-2.452	0.054
Administration of cilostazol	0.39	0.248-0.610	<0.001
Rutherford classification	1.17	0.960-1.429	0.1118
TASC II C/D	2.41	1.315-4.403	0.0044
Chronic total occlusion	0.72	0.415-1.259	0.2515
Stent fracture	2.28	1.295-4.001	0.0043
Smart stent	0.90	0.528-1.520	0.6837
Lesion length ≥ 100mm	1.37	0.738-2.536	0.3189